Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + nab-paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy is an investigational regimen being evaluated for the treatment of recurrent or metastatic cervical cancer, particularly in patients who have progressed on prior anti-PD-(L)1 therapy. The regimen consists of QL1706, a bifunctional MabPair biologic developed by Qilu Pharmaceutical that combines the anti-PD-1 monoclonal antibody iparomlimab and the anti-CTLA-4 monoclonal antibody tuvonralimab in a fixed 2:1 ratio. This immunotherapy is combined with nab-paclitaxel (an albumin-bound nanoparticle formulation of paclitaxel) and bevacizumab (an anti-VEGF monoclonal antibody). The therapeutic strategy aims to overcome resistance to single-agent checkpoint inhibition by simultaneously targeting the PD-1 and CTLA-4 pathways while utilizing the cytotoxic effects of chemotherapy and the anti-angiogenic properties of bevacizumab to enhance anti-tumor activity.
- Other names
- QL1706 + nab-paclitaxel + bevacizumabiparomlimab and tuvonralimab + nab-paclitaxel + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + nab-paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + nab-paclitaxel + bevacizumab.